Putative molecular signatures for the imaging of prostate cancer

Expert Review of Molecular Diagnostics

Volumn 10, Issue 1, 2010, Pages 65-74

  Yongliang, Yang S ^a,b   Adelstein, James ^a   Kassis, Amin I ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b DALIAN UNIVERSITY OF TECHNOLOGY   (China)

Author keywords

Imaging; Molecular signature; Prostate cancer; Prostate specific antigen

Indexed keywords

ALPHA INTEGRIN; BIOLOGICAL MARKER; CD51 ANTIGEN; CHEMOKINE RECEPTOR; DISINTEGRIN; FLUORODEOXYGLUCOSE F 18; GAMMA GLUTAMYL HYDROLASE; HEPSIN; METALLOPROTEINASE; PROSTATE SPECIFIC ANTIGEN; SERINE;

ACCURACY; BIOINFORMATICS; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GENOMICS; HUMAN; METABOLOMICS; POSITRON EMISSION TOMOGRAPHY; PROSTATE CANCER; PROTEOMICS; REVIEW; SENSITIVITY AND SPECIFICITY;

ANIMALS; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 74749094140     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/erm.09.73     Document Type: Review

References (66)

1. American Cancer Society. Cancer Facts and Figures 2009. American Cancer Society, GA, USA (2009).
2. Narain V, Cher ML, Wood DP Jr. Prostate cancer diagnosis, staging and survival. Cancer Metastasis Rev. 21, 17-27 (2002).
3. Godley PA. Prostate cancer screening: promise and peril - a review. Cancer Detect. Prev. 23, 316-324 (1999).
4. Barry MJ. Clinical practice. Prostatespecific-antigen testing for early diagnosis of prostate cancer. N. Engl. J. Med. 344, 1373-1377 (2001).
5. Parekh DJ, Ankerst DP, Troyer D et al. Biomarkers for prostate cancer detection. J. Urol. 178, 2252-2259 (2007).
6. Lee TH, Kantoff PW, McNaughton-Collins MF. Screening for prostate cancer. N. Engl. J. Med. 360, E18 (2009).
7. Thompson IM, Pauler DK, Goodman PJ et al. Prevalence of prostate cancer among men with a prostate-specific antigen level ≤4.0 ng per milliliter. N. Engl. J. Med. 350, 2239-2246 (2004).
8. Andriole GL, Grubb RL, III, Buys SS et al. The PLCO Project Team. Mortality results from a randomized prostate-cancer screening trial. N. Engl. J. Med. 360, 1310-1319 (2009).
9. Pienta KJ. Critical appraisal of prostatespecific antigen in prostate cancer screening: 20 years later. Urology 73, S11-S20 (2009).
10. Bensalah K, Lotan Y, Karam JA, Shariat SF. New circulating biomarkers for prostate cancer. Prostate Cancer Prostatic Dis. 11, 112-120 (2008).
11. Tricoli JV, Schoenfeldt M, Conley BA. Detection of prostate cancer and predicting progression: current and future diagnostic markers. Clin. Cancer Res. 10, 3943-3953 (2004).
12. Levesque M, Yu H, D'Costa M et al. Immunoreactive prostate-specific antigen in lung tumors. J. Clin. Lab. Anal. 9, 375-379 (1995).
13. Varambally S, Yu J, Laxman B et al. Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell 8, 393-406 (2005).
14. Bradford TJ, Tomlins SA, Wang X, Chinnaiyan AM. Molecular markers of prostate cancer. Urol. Oncol. 24, 538-551 (2006).
15. Pospisil P, Iyer LK, Adelstein SJ, Kassis AI. A combined approach to data mining of textual and structured data to identify cancer-related targets. BMC Bioinformatics 7, 354 (2006).
16. Yang Y, Iyer LK, Adelstein SJ, Kassis AI. Integrative genomic data mining for discovery of potential blood-borne biomarkers for early diagnosis of cancer. PLoS ONE 3, E3661 (2008).
17. Yang Y, Adelstein SJ, Kassis AI. Target discovery from data mining approaches. Drug Discov. Today 14, 147-154 (2009).
18. Luo J, Zha S, Gage WR et al. α-methylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer Res. 62, 2220-2226 (2002).
19. Rubin MA, Zhou M, Dhanasekaran SM et al. α-methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA 287, 1662-1670 (2002).
20. Varambally S, Dhanasekaran SM, Zhou M et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419, 624-629 (2002).
21. Rehman I, Azzouzi AR, Catto JW et al. Proteomic analysis of voided urine after prostatic massage from patients with prostate cancer: a pilot study. Urology 64, 1238-1243 (2004).
22. Sardana G, Jung K, Stephan C, Diamandis EP. Proteomic analysis of conditioned media from the PC3, LNCaP, and 22Rv1 prostate cancer cell lines: discovery and validation of candidate prostate cancer biomarkers. J. Proteome Res. 7(8), 3329-3338 (2008).
23. Sardana G, Dowell B, Diamandis EP. Emerging biomarkers for the diagnosis and prognosis of prostate cancer. Clin. Chem. 54, 1951-1960 (2008).
24. Sreekumar A, Poisson LM, Rajendiran TM et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 457, 910-914 (2009).
25. Jordan KW, Cheng LL. NMR-based metabolomics approach to target biomarkers for human prostate cancer. Expert Rev. Proteomics 4(3), 389-400 (2007).
26. Rhodes DR, Chinnaiyan AM. Bioinformatics strategies for translating genome-wide expression analyses into clinically useful cancer markers. Ann. NY Acad. Sci. 1020, 32-40 (2004).
27. Rhodes DR, Kalyana-Sundaram S, Mahavisno V et al. Oncomine 3.0, genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia 9, 166-180 (2007).
28. Chen YP, Chen F. Identifying targets for drug discovery using bioinformatics. Expert Opin. Ther. Targets 12, 383-389 (2008).
29. Klee EW, Finlay JA, McDonald C et al. Bioinformatics methods for prioritizing serum biomarker candidates. Clin. Chem. 52, 2162-2164 (2006).
30. Weissleder R. Molecular imaging in cancer. Science 312, 1168-1171 (2006).
31. Weissleder R, Pittet MJ. Imaging in the era of molecular oncology. Nature 452, 580-589 (2008).
32. Karam JA, Mason RP, Koeneman KS, Antich PP, Benaim EA, Hsieh JT. Molecular imaging in prostate cancer. J. Cell. Biochem. 90, 473-483 (2003).
33. Hricak H, Choyke PL, Eberhardt SC et al. Imaging prostate cancer: a multidisciplinary perspective. Radiology 243, 28-53 (2007).
34. Futterer JJ, Barentsz J, Heijmijnk ST. Imaging modalities for prostate cancer. Expert Rev. Anticancer Ther. 9, 923-937 (2009).
35. Jager PL, de Korte MA, Lub-de Hooge MN et al. Molecular imaging: what can be used today. Cancer Imaging 5(Spec. No. A), S27-S32 (2005).
36. Jadvar H. Molecular imaging of prostate cancer: a concise synopsis. Mol. Imaging 8, 56-64 (2009).
37. Albers MJ, Bok R, Chen AP et al. Hyperpolarized 13C lactate, pyruvate, and alanine: noninvasive biomarkers for prostate cancer detection and grading. Cancer Res. 68(20), 8607-8615 (2008).
38. Davis MI, Bennett MJ, Thomas LM, Bjorkman PJ. Crystal structure of prostate-specific membrane antigen, a tumor marker and peptidase. Proc. Natl Acad. Sci. USA 102, 5981-5986 (2005).
39. Banerjee SR, Foss CA, Castanares M et al. Synthesis and evaluation of technetium-99m- and rhenium-labeled inhibitors of the prostate-specific membrane antigen (PSMA). J. Med. Chem. 51, 4504-4517 (2008).
40. Serda RE, Adolphi NL, Bisoffi M, Sillerud LO. Targeting and cellular trafficking of magnetic nanoparticles for prostate cancer imaging. Mol. Imaging 6, 277-288 (2007).
41. Foss CA, Mease RC, Fan H et al. Radiolabeled small-molecule ligands for prostate-specific membrane antigen: in vivo imaging in experimental models of prostate cancer. Clin. Cancer Res. 11, 4022-4028 (2005).
42. Kularatne SA, Zhou Z, Yang J et al. Design, synthesis, and preclinical evaluation of prostate-specific membrane antigen targeted 99mTc-radioimaging agents. Mol. Pharm. 6, 790-800 (2009).
43. Elsasser-Beile U, Reischl G, Wiehr S et al. PET imaging of prostate cancer xenografts with a highly specific antibody against the prostate-specific membrane antigen. J. Nucl. Med. 50, 606-611 (2009).
44. Humblet V, Lapidus R, Williams LR et al. High-affinity near-infrared fluorescent small-molecule contrast agents for in vivo imaging of prostate-specific membrane antigen. Mol. Imaging 4, 448-462 (2005).
45. Gelmann EP, Semmes OJ. Expression of genes and proteins specific for prostate cancer. J. Urol. 172, S23-S27 (2004).
46. Kelly KA, Setlur SR, Ross R et al. Detection of early prostate cancer using a hepsin-targeted imaging agent. Cancer Res. 68, 2286-2291 (2008).
47. Ho NH, Harapanhalli RS, Dahman BA et al. Synthesis and biologic evaluation of a radioiodinated quinazolinone derivative for enzyme-mediated insolubilization therapy. Bioconjug. Chem. 13, 357-364 (2002).
48. Chen K, Wang K, Kirichian AM et al. In silico design, synthesis, and biological evaluation of radioiodinated quinazolinone derivatives for alkaline phosphatasemediated cancer diagnosis and therapy. Mol. Cancer Ther. 5, 3001-3013 (2006).
49. Chen K, Al Aowad AF, Adelstein SJ, Kassis AI. Molecular-docking-guided design, synthesis, and biologic evaluation of radioiodinated quinazolinone prodrugs. J. Med. Chem. 50, 663-673 (2007).
50. Pospisil P, Wang K, Al Aowad AF et al. Computational modeling and experimental evaluation of a novel prodrug for targeting the extracellular space of prostate tumors. Cancer Res. 67, 2197-2205 (2007).
51. Wang K, Kirichian AM, Al Aowad AF, Adelstein SJ. Evaluation of chemical, physical, and biologic properties of tumor-targeting radioiodinated quinazolinone derivative. Bioconjugate Chem. 18, 754-764 (2007).
52. Kassis AI, Korideck H, Wang K et al. Novel prodrugs for targeting diagnostic and therapeutic radionuclides to solid tumors. Molecules 13, 391-404 (2008).
53. Engl T, Relja B, Marian D et al. CXCR4 chemokine receptor mediates prostate tumor cell adhesion through α5 and β3 integrins. Neoplasia 8, 290-301 (2006).
54. Taichman RS, Cooper C, Keller ET et al. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res. 62, 1832-1837 (2002).
55. 111In-labeled peptide derivative targeting a chemokine receptor, CXCR4, for imaging tumors. Nucl. Med. Biol. 33, 489-494 (2006).
56. Jacobson O, Weiss ID, Szajek L, Farber JM. 64Cu-AMD3100 - a novel imaging agent for targeting chemokine receptor CXCR4. Bioorg. Med. Chem. 17, 1486-1493 (2009).
57. McCulloch DR, Akl P, Samaratunga H et al. Expression of disintegrin metalloprotease, ADAM-10, in prostate cancer and its regulation by dihydrotestosterone, insulin-like growth factor I, and epidermal growth factor in the prostate cancer cell model LMCaP. Clin. Cancer Res. 10, 314-323 (2004).
58. Najy AJ, Day KC, Day ML. ADAM15 supports prostate cancer metastasis by modulating tumor cell-endothelial cell interaction. Cancer Res. 68, 1092-1099 (2008).
59. Goel HL, Li J, Kogan S, Languino LR. Integrins in prostate cancer progression. Endocr. Relat. Cancer 15, 657-664 (2008).
60. Wang X, Ferreira AM, Shao Q et al. β3 integrins facilitate matrix interactions during transendothelial migration of PC3 prostate tumor cells. Prostate 63, 65-80 (2005).
61. 3-targeted magnetic resonance imaging. Nat. Med. 4, 623-626 (1998).
62. Beer AJ, Haubner R, Sarbia M et al. Positron emission tomography using [18F] Galacto-RGD identifies the level of integrin α(v)β 3 expression in man. Clin. Cancer Res. 12, 3942-3949 (2006).
63. Ellegala DB, Leong-Poi H, Carpenter JE et al. Imaging tumor angiogenesis with contrast ultrasound and microbubbles targeted to α (v)β3. Circulation 108, 336-341 (2003). (Pubitemid 36899026)
64. Mitchell PS, Parkin RK, Kroh EM, Fritz BR et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl Acad. Sci. USA 105, 10513-10518 (2008).
65. Kim HJ, Chung JK, Hwang do W, Lee DS et al. In vivo imaging of mir-221 biogenesis in papillary thyroid carcinoma. Mol. Imaging Biol. 11, 71-78 (2009).
66. Rhodes DR, Yu J, Shanker K et al. Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. Proc. Natl Acad. Sci. USA 101(25), 9309-9314 (2004).